

IT IS CLAIMED:

1. An isolated polypeptide comprising a sequence having at least 90% sequence identity to SEQ ID NO: 2.

5

2. The isolated polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 2.

3. The isolated polypeptide of claim 1, having the amino sequence SEQ ID NO: 2, including conservative amino acid substitutions thereto, wherein said substitutions do not alter said sequence by more than about 10%.

4. The isolated polypeptide of claim 1, having the amino acid sequence SEQ ID NO: 2.

5. An isolated polynucleotide comprising a sequence which encodes a polypeptide having at least 90% sequence identity to SEQ ID NO: 2.

6. The isolated polynucleotide of claim 5, comprising a sequence which encodes a polypeptide having at least 95% sequence identity to SEQ ID NO: 2.

20

7. The isolated polynucleotide of claim 5, comprising the sequence SEQ ID NO: 1.

8. An expression vector containing the polynucleotide of any of claims 5-7, and regulatory elements effective for expression of the polynucleotide in a suitable host.

25

9. The vector of claim 8, wherein said vector is a baculovirus vector suitable for use in an insect cell expression system.

10. A method of inducing an immune response against a tumor-associated antigen in a mammalian subject, comprising

administering to the subject an immunogenic dosage of a composition comprising a xenogeneic form of said tumor-related antigen from a different mammalian species.

11. The method of claim 10, wherein said tumor-associated antigen is human prostatic acid phosphatase (PAP) and said xenogeneic antigen includes a non-human PAP.

12. The method of claim 11, wherein said xenogeneic antigen is mouse PAP.

5

13. The method of claim 12, wherein said mouse PAP is selected according to any of claims 1-4.

14. The method of claim 13, wherein said xenogeneic antigen is produced in insect cells.

10

15. The method of any of claims 10-14, wherein said xenogeneic antigen composition includes a viral expression system which expresses said xenogeneic antigen.

16. The method of claim 15, wherein said viral expression system is selected from the group consisting of vaccinia virus, adeno virus and adeno-like virus.

15

17. The method of any of claims 10-14, wherein said xenogeneic antigen composition includes a dendritic cell pulsed *in vitro* with said xenogeneic antigen.

20

18. An immunogenic composition for eliciting an immune response against a tumor-related antigen in a mammalian species, comprising
a recombinant virus that expresses a xenogeneic form of said tumor-related antigen.

25

19. The immunogenic composition of claim 18, wherein said xenogeneic form of said tumor-related antigen is a non-human prostatic acid phosphatase (PAP).

20. The immunogenic composition of claim 19, wherein said PAP is selected according to any of claims 1-4.

30

21. An immunogenic composition for eliciting a cellular immune response against a tumor-related antigen in a mammalian species, comprising
a dendritic cell that has been pulsed *in vitro* with a xenogeneic form of said tumor-related antigen.

35

22. The composition of claim 21, wherein said tumor-related antigen includes a non-human prostatic acid phosphatase.

23. The composition of claim 22, wherein said PAP is selected according to any of claims 1-4.

IT IS CLAIMED:

Sub B4
1. An isolated polypeptide comprising a sequence having at least 90% sequence identity to SEQ ID NO: 2.

5
2. The isolated polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 2.

10
3. The isolated polypeptide of claim 1, having the amino sequence SEQ ID NO: 2, including conservative amino acid substitutions thereto, wherein said substitutions do not alter said sequence by more than about 10%.

4. The isolated polypeptide of claim 1, having the amino acid sequence SEQ ID NO: 2.

15
5. An isolated polynucleotide comprising a sequence which encodes a polypeptide having at least 90% sequence identity to SEQ ID NO: 2.

20
6. The isolated polynucleotide of claim 5, comprising a sequence which encodes a polypeptide having at least 95% sequence identity to SEQ ID NO: 2.

7. The isolated polynucleotide of claim 5, comprising the sequence SEQ ID NO: 1.

25
8. An expression vector containing the polynucleotide of any of claims 5-7, and regulatory elements effective for expression of the polynucleotide in a suitable host.

9. The vector of claim 8, wherein said vector is a baculovirus vector suitable for use in an insect cell expression system.

30
10. A method of inducing an immune response against ~~a tumor associated antigen~~ in a mammalian subject, comprising
administering to the subject an immunogenic dosage of a composition comprising a xenogeneic form of ~~said tumor related antigen~~ ^{PAP} from a different mammalian species.

~~11. The method of claim 10, wherein said tumor-associated antigen is [human prostatic acid phosphatase (PAP)] and said xenogeneic antigen includes a non-human PAP/~~

11. ~~12.~~ The method of claim ~~10~~ ¹¹, wherein said xenogeneic ~~antigen~~ ^{form of PAP} is mouse PAP.

12. ~~13.~~ The method of claim ~~12~~ ¹¹, wherein said mouse PAP is selected according to any of claims

13. ~~14.~~ The method of claim ~~13~~ ¹², wherein said xenogeneic antigen is produced in insect cells.

14. ~~15.~~ The method of any of claims ~~10-14~~ ¹³, wherein said xenogeneic ~~antigen~~ ^{form of PAP} composition includes a viral expression system which expresses said xenogeneic ~~antigen~~ ^{form of PAP}.

15. ~~16.~~ The method of claim ~~15~~ ¹⁴, wherein said viral expression system is selected from the group consisting of vaccinia virus, adeno virus and adeno-like virus.

16. ~~17.~~ The method of any of claims ~~10-14~~ ¹³, wherein said xenogeneic ~~antigen~~ ^{form of PAP} composition includes a dendritic cell pulsed *in vitro* with said xenogeneic ~~antigen~~ ^{form of PAP}.

17. ~~18.~~ An immunogenic composition for eliciting an immune response against a ~~tumor-related antigen~~ ^{PAP} in a mammalian species, comprising a recombinant virus that expresses a xenogeneic form of ~~said tumor-related antigen~~ ^{PAP}.

18. ~~19.~~ The immunogenic composition of claim ~~18~~ ¹⁷, wherein said xenogeneic form of ~~said tumor-related antigen~~ ^{PAP} is a non-human prostatic acid phosphatase (PAP).

19. ~~20.~~ The immunogenic composition of claim ~~19~~ ¹⁸, wherein said PAP is selected according to any of claims 1-4.

20. ~~21.~~ An immunogenic composition for eliciting a cellular immune response against a ~~tumor-related antigen~~ ^{PAP} in a mammalian species, comprising a dendritic cell that has been pulsed *in vitro* with a xenogeneic form of ~~said tumor-related antigen~~ ^{PAP}.

PAP

21.
~~22.~~ The composition of claim 20, wherein said ~~tumor related antigen~~ includes a non-human prostatic acid phosphatase.

22.
~~23.~~ The composition of claim ~~22~~, wherein said PAP is selected according to any of claims

5 14.

ADD
B5

AMENDED SHEET